Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Clinical trial NCT04807673 · RECRUITING

Trial details

NCT number: NCT04807673
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma

Start date: 2021-12-01
Primary completion: 2023-12-31
Enrollment: 342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.